Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 11:12:814302.
doi: 10.3389/fphar.2021.814302. eCollection 2021.

Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis

Yanfei Lu  1 , Zhenbin Wei  1 , Gaohui Yang  1 , Yongrong Lai  1 , Rongrong Liu  1
Affiliations
Review

Investigating the Efficacy and Safety of Thalidomide for Treating Patients With ß-Thalassemia: A Meta-Analysis

Yanfei Lu et al. Front Pharmacol. .

Abstract

At present, the main therapies for ß-thalassemia patients include regular blood transfusion and iron chelation, associating with a number of limitations. Thalidomide, a fetal hemoglobin (HbF) inducer that promotes γ-globin gene expression, has been reported to be effective for ß-thalassemia. Thus, this meta-analysis was conducted to assess the efficacy and safety of thalidomide for treating patients with ß-thalassemia. We searched the related studies from eight databases published from inception until December 1, 2021. The R 4.0.5 language programming was used to perform meta-analysis. After screening of retrieved articles, 12 articles were included that enrolled a total of 451 patients. The Cochrane Collaboration risk assessment tool was used to evaluate the quality and the bias risk of the randomized controlled trials (RCTs), and non randomized trials were assessed using Newcastle-Ottawa Scale (NOS). After treatment with thalidomide, the pooled overall response rate (ORR) was 85% (95% confidence interval (CI): 80-90%), and the pooled complete response rate (CRR) was 54% (95% confidence interval: 31-76%). Compared with the placebo group, the thalidomide group had higher odds of overall response rate (odds ratio = 20.4; 95% CI: 6.75-61.64) and complete response rate (odds ratio = 20.4; 95% CI: 6.75-61.64). A statistically significant increase in hemoglobin level and HbF level after treatment, while there was no statistically significant difference in adult hemoglobin (HbA) level, spleen size, and serum ferritin. According to the results of ORR and CRR, transfusion-dependent thalassemia (TDT) patients showed remarkable efficacy of thalidomide, 83 and 52% respectively. So we analyzed 30 transfusion-dependent thalassemia patients from three studies and found that the most frequent ß-globin gene mutations were CD41-42 (-TCTT), while response to thalidomide did not show any statistically significant relationship with XmnI polymorphism or CD41-42 (-TCTT) mutation. About 30% of patients experienced mild adverse effects of thalidomide. Collectively, thalidomide is a relatively safe and effective therapy to reduce the blood transfusion requirements and to increase Hb level in patients with ß-thalassemia.

Keywords: hemoglobin level; meta-analysis; thalidomide; therapy; ß-thalassemia.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
Flowchart of study selection process. NOS, Newcastle-Ottawa Scale.
FIGURE 2
FIGURE 2
A forest plot illustrating overall response rate in population-based subgroups.
FIGURE 3
FIGURE 3
A forest plot illustrating complete response rate in population-based subgroups.
FIGURE 4
FIGURE 4
A forest plot illustrating Hb level (g/dl) after the treatment of thalidomide in population-based subgroups.
FIGURE 5
FIGURE 5
A forest plot illustrating HbF level (%) after the treatment of thalidomide.
FIGURE 6
FIGURE 6
A forest plot illustrating adverse effects of thalidomide.
See this image and copyright information in PMC

References

    1. Aerbajinai W., Zhu J., Gao Z., Chin K., Rodgers G. P. (2007). Thalidomide Induces Gamma-Globin Gene Expression through Increased Reactive Oxygen Species-Mediated P38 MAPK Signaling and Histone H4 Acetylation in Adult Erythropoiesis. Blood 110 (8), 2864–2871. 10.1182/blood-2007-01-065201 - DOI - PMC - PubMed
    1. Algiraigri A. H., Wright N. A. M., Paolucci E. O., Kassam A. (2017a). Hydroxyurea for Lifelong Transfusion-dependent β-thalassemia: A Meta-Analysis. Pediatr. Hematol. Oncol. 34 (8), 435–448. 10.1080/08880018.2017.1354948 - DOI - PubMed
    1. Algiraigri A. H., Wright N. A. M., Paolucci E. O., Kassam A. (2017b). Hydroxyurea for Nontransfusion-dependent β-thalassemia: A Systematic Review and Meta-Analysis. Hematol. Oncol. Stem Cel Ther 10 (3), 116–125. 10.1016/j.hemonc.2017.02.002 - DOI - PubMed
    1. Amirshahrokhi K., Khalili A. R. (2015). The Effect of Thalidomide on Ethanol-Induced Gastric Mucosal Damage in Mice: Involvement of Inflammatory Cytokines and Nitric Oxide. Chem. Biol. Interact 225, 63–69. 10.1016/j.cbi.2014.11.019 - DOI - PubMed
    1. Angastiniotis M., Modell B. (1998). Global Epidemiology of Hemoglobin Disorders. Ann. N. Y Acad. Sci. 850, 251–269. 10.1111/j.1749-6632.1998.tb10482.x - DOI - PubMed